Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 2.8M | 84.1% |
| Gross Profit | 2.7M | 85.9% |
| Cost of Revenue | 39,000 | 8.3% |
| Operating expense | 23M | 182.3% |
| Net Income | -30M | 636% |
| EBITDA | -4.8M | 26.7% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 91M | 18.8% |
| Total Liabilities | 44M | 28.1% |
| Total Equity | 48M | 38.8% |
| Shares Outstanding | 228M | 1% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -5.5M | 13.4% |
| Cash from investing | -14,000 | 100.7% |
| Cash from financing | -310,000 | 106.1% |
EPS
Financial Highlights for Lineage Cell Therapeutics in Q2 '25
Lineage Cell Therapeutics reported a revenue of 2.8M, which is a 84.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 2.7M, marking a 85.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 39,000, a 8.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 23M, showing a 182.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -30M, showing a -636% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -4.8M, showing a 26.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Lineage Cell Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
